ClinicalTrials.gg
RecruitingNCT06906081FibroCANUpdated May 25, 2025

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

A Phase 2 interventional study of Kerendia (Finerenone, BAY94-8862) and Placebo in Cardiovascular Autonomic Neuropathy, Type 2 Diabetes and Diabetic Neuropathies, sponsored by Peter Rossing. Recruiting at 2 sites in Denmark. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Peter Rossing · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing finerenone in Diabetes Mellitus, Type 2 — 5 open to participants now, 6 under way, none of them phase 3. finerenone · Diabetes Mellitus, Type 2.

Planned enrollment
7th of 13
100 · median 100
Started
2025
the only one that year
Phase 2
3 of 13
1 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Peter Rossing

Among the 13 studies testing finerenone in Diabetes Mellitus, Type 2, this one is the 7th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 2, and was the 10th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 13 studies testing finerenone in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing finerenone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Diabetic neuropathy is a serious and common complication of diabetes that currently has no cure. One form of this condition is cardiovascular autonomic neuropathy (CAN), which affects about 20% of people with diabetes-an estimated 100 million people worldwide. CAN is a significant risk factor for death and health problems like heart disease and kidney damage, and may contribute to the high rates of cardiovascular-related deaths in people with diabetes.

This study is a double-blind, randomized, placebo-controlled, two-center trial. The study aims to test whether finerenone can treat cardiovascular autonomic neuropathy in patients with type 2 diabetes. The trial will evaluate the effects of 78 weeks of treatment with finerenone or a placebo, assigned randomly in a 1:1 ratio, on early-stage cardiovascular autonomic neuropathy. The trial will include 100 participants with type 2 diabetes. Additionally, the study will investigate how the treatment impacts other types of neuropathy and related pathological mechanisms.

03

Conditions studied

  • Cardiovascular Autonomic Neuropathy
  • Type 2 Diabetes
  • Diabetic Neuropathies

Keywords

  • Mineralocorticoid receptor antagonist (MRA)
  • Cardiovascular autonomic neuropathy
  • Type 2 Diabetes
  • Diabetic Neuropathy
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be included in this study the participants must fulfill the following inclusion criteria.

  • Given
  • Type 2 diabetes defined by WHO criteria
  • Aged 40 ≥ at inclusion
  • Pathological E/I ratio (Mean value of three measures)

Exclusion criteria Participants will be excluded in one or more of the following criteria are met.

  • No CAN (no abnormal CARTs)
  • Definite CAN (more than one abnormal CART)
  • >100 mmol/L
  • Treatment with potassium-sparing diuretics (amiloride) or MRAs e.g., spironolactone or eplerenone which cannot be discontinued 4 weeks prior to screening visit. The patient's primary physician, who is not involved in this study, will determine if discontinuation is possible.
  • Atrial fibrillation/flutter
  • Congestive heart failure ( class 3-4)
  • History of cardiac arrhythmia
  • Severe forms of respiratory disease including asthma and
  • Any nondiabetic cause of neuropathy
  • All female subjects of (WOCBP) must have a negative result of a highly sensitive urine HCG (pregnancy test) performed at screening. Subjects of childbearing potential must agree to use a highly effective form of throughout the duration of the study (list of definition on WOCBP and accepted contraception in appendix A).
  • Severe hepatic impairment
  • Lactose intolerance
  • Breastfeeding
  • Nephropathy requiring dialysis
  • Beta-blocker-use
  • Hyperkalemia at screening visit (plasma potassium >4.8 mmol/l)
  • \< 25 ml/min/1.73m2
  • Potassium plasma > 4.8 mmol/l (at randomization)
  • Treatment with strong -inhibitors (e.g. Itraconazol, ketoconazol, ritonavir, cobicistat, clarithromycin) which cannot be discontinued 4 weeks prior to screening visit
  • Treament with moderate to strong CYP3A4-induceres (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort or efavirenz) which cannot be discontinued 4 weeks prior to screening visit
  • Have received chemotherapeutic treatment within last 12 months
  • Grapefruit consumption that cannot be discontinued during the study period
  • Inability to complete study protocol, assessed to investigator
  • Not able to read, write and/or understand Danish
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Finerenone (active)

    Drug: Kerendia (Finerenone, BAY94-8862)

Interventions

  • DrugFinerenoneStudies of FinerenoneFinerenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Titration of finerenone will be based on baseline eGFR. Participants with eGFR \> 60 mL/min/1.73m² will start on a 20mg dosage. Medication dosage will be increased to 40 mg after one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level. Participants with eGFR \< 60 and \>25 Participants with eGFR \< 60 mL/min/1.73m² (and eGFR \< 25 mL/min/1.73m²) will start on a 10mg dosage. Medication dosage will be increased to 20 mg after one month if serum potassium \< 4.8 mmol/l. Subsequently, Medication dosage will be increased to 40 mg after an additional one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level. Finerenone is administered orally as immediate release tablets.

  • DrugPlacebo

    Placebo tablets matching BAY94-8862 are administered orally.

06

What researchers measure

Primary outcomes

  1. Between-group (finerenone vs. placebo) difference in changes on the CART E/I ratio

    Measured by vagus device

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

Secondary outcomes

  1. Between-group (finerenone vs. placebo) difference in changes on the CART R/S ratio

    R/S ratio (CART). Measured by Vagus device.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  2. Between-group (finerenone vs. placebo) difference in changes on the CART Valsalva manoeuvre.

    Valsalva manoeuvre (CART). Measured by Vagus device.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  3. Between-group (finerenone vs. placebo) differences in changes on heart rate variability (HRV) by SDNN and RMSSD

    Measured by vagus device as SDNN (Standard Deviation of Normal-to-Normal interbeat) intervals and RMSSD (Root Mean Square of Successive Differences between normal heartbeats). SDNN and RMSSD is measured in milliseconds.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  4. Between-group (finerenone vs. placebo) differences in changes on heart rate variability (HRV) by high and low frequency power.

    Measured by vagus device as low and high frequency power in the unit milliseconds squared.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  5. Between-group (finerenone vs. placebo) differences in changes on fibrosis markers in serum

    Serum PRO-C6 and PRO-C3 assessed by ELISA.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78. Skin biopsies on week 0, week 36 and week 78.

  6. Between-group (finerenone vs. placebo) differences in changes on fibrosis markers in skin biopsies by PRO-C6

    Pro-C6 by immunostaining

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at week 0, 36 and 78

  7. Between-group (finerenone vs. placebo) differences in changes on fibrosis markers in skin biopsies by C3M

    C3M by immunostaining

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at week 0, 36 and 78

Other outcomes

  1. Between-group (finerenone vs. placebo) differences in changes on inflammation markers

    Olink inflammation markers will be measured with PCR.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  2. Between-group (finerenone vs. placebo) differences in changes on markers of retinopathy

    Markers of retinopathy (nonproliferativ/proliferative retinopathy and retinal nerve fibre layer thickness by optical coherence tomography)

    Time frame: From enrollement to the end of treatment at 78 weeks. Tested at week 0, week 36 and week 78.

  3. Between-group (finerenone vs. placebo) differences in changes on markers of corneal neuropathy by CNFD

    Overall to quantify the severity of small nerve fibre damage by confocal corneal microscopy. Quantified by corneal nerve fiber density (CNFD) measured in fibers per mm2.

    Time frame: From enrollement to the end of treatment at 78 weeks. Tested at week 0, week 36 and week 78.

  4. Between-group (finerenone vs. placebo) differences in changes on markers of corneal by neuropathy by CNBD

    Overall to quantify the severity of small nerve fibre damage by confocal corneal microscopy. Quantified including corneal nerve branch density (CNBD) measured in branches per mm2.

    Time frame: From enrollement to the end of treatment at 78 weeks. Tested at week 0, week 36 and week 78.

  5. Between-group (finerenone vs. placebo) differences in changes on markers of corneal neuropathy by DCF, DCP, NCF and NCP

    Overall to quantify the severity of small nerve fibre damage by confocal corneal microscopy. Quantified including corneal nerve fiber length (CNFL), dendritic cells with contact to nerve fiber (DCF), dendritic cells without contact to nerve fiber (DCP), non-dendritic cells with contact to nerve fiber (NCF) and non-dendritic cells without contact to nerve fiber (NCP). All measured in cells per mm2.

    Time frame: From enrollement to the end of treatment at 78 weeks. Tested at week 0, week 36 and week 78.

  6. Between-group (finerenone vs. placebo) difference on Cardiac vagal tone

    Measured with eMotion Faros

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  7. Between-group (finerenone vs. placebo) difference in changes on questionnaires for painful and painless neuropathy DN4

    The following neuropathy questionnaires will be used to assess peripheral neuropathy: - The Douleur Neuropathique 4 (DN4) to assess painful peripheral neuropathy with a cut-off ≥ 4.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  8. Between-group (finerenone vs. placebo) difference in changes on questionnaires for painful and painless neuropathy MNSI

    The following neuropathy questionnaires will be used to assess peripheral neuropathy: Michigan Neuropathy Screening Instrument (MNSI) with ≥ 4 a cut-off.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  9. Between-group (finerenone vs. placebo) difference in changes on orthostatic blood pressure testing

    Orthostatic hypotension will be defined as decline in systolic blood pressure ≥ 20 mmHg or diastolic blood pressure ≥ 10 mmHg or a decrease in systolic blood pressure to \< 90. From position change from lying to standing.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  10. Between-group (finerenone vs. placebo) difference in changes on Sudomotor function of the skin in hands and feet (Sudoscan)

    Measured with: (Sudoscan)

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  11. Between-group (finerenone vs. placebo) difference in changes of questionnaires for autonomic neuropathy Compass-31

    Measured with compass-31.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  12. Between-group (finerenone vs. placebo) difference in changes of questionnaires for autonomic neuropathy GCSI

    Measured with GCSI.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  13. Between-group (finerenone vs. placebo) difference in changes of sural nerve conduction and amplitude (DPNCheck)

    Nerve conduction velocity and amplitude of the sural nerve will be assessed the average of three measures on both the left and right leg by use of the NC-StatR DPNCheck (NeuroMetrix, Inc., Waltham, USA). Age- and height-stratified perception thresholds will be applied.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  14. Between-group (finerenone vs. placebo) difference in changes of vibration sensation threshold (Biothesiometry)

    Vibration perception threshold (VPT) will be measured by using biothesiometry (Bio-medical instruments, Ohio, USA) applied to the distal tip of the first toe on both feet. Cut-off above 25 V and age-sex-height specific cut-offs was applied (38, 39). Biothesiometry measurements will be repeated three times and averaged of the measures will be used.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  15. Between-group (finerenone vs. placebo) difference in changes of pain sensation

    Pain sensation will be assessed by pinprick (Neuropen, Owen Mumford Ltd, Oxford, UK). Pinpricks will be applied proximal to the nail on the first dorsal, third and fifth toes on each foot. DPN will be defined as no pain at any tested location.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  16. Between-group (finerenone vs. placebo) difference in changes of light touch sensation

    Ten-gram monofilament (Neuropen, Owen Mumford Ltd, Oxford, UK) will be applied three times at four points on the plantar aspect of the foot (first toe, proximal to the first toe, third toe and fifth toe) in addition to the proximal to the nail on the first dorsal, third and fifth toes on each foot. All measures will be obtained on both feet. DPN will be defined as absence of sensation at all locations.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  17. Between-group (finerenone vs. placebo) difference in changes of cold and warm sensation of foot and lower leg

    Thermal sensation (25°C and 40°C) will be assessed by applying metal rolls bilaterally on the dorsal side of the first toe, dorsum of the foot and the anterior part of the low leg from 10 centimeter above the lateral malleolus and 10 centimeter proximately by Rolltemp-II (Somedic SenseLab AB). All measures will be obtained on both legs. Abnormal sensation will be defined as bilateral abnormalities at the toes, either with or without an abnormal sensation of the foot and leg.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  18. Between-group (finerenone vs. placebo) difference in changes of ancle and patella reflexes (Reflex hammer)

    Ancle and patella reflexes will be perform using a reflex hammer on both sides.

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 12, week 24, week 36, week 52 and week 78

  19. Between-group (finerenone vs. placebo) difference in changes of intraepidermal nerve fiber density (IENFD)

    Intraepidermal nerve fiber density (IENFD quantified following international guidelines

    Time frame: From baseline to the end of treatment at 78 weeks. Tested at screening, week 0, week 36 and week 78

  20. The association between serum fibrosis markers and level of peripheral neuropathy in type 2 diabetes

    Measurement of baseline fibrosis markers in serum and in skin samples and compare to level of peripheal neuropathy measured at baseline

    Time frame: Data analysis after baseline sampling

  21. The association between serum fibrosis markers and level of autonomic neuropathy in type 2 diabetes

    Measurement of baseline fibrosis markers in serum and compare to level of autonomic neuropathy measured at baseline

    Time frame: Data analysis after baseline sampling

07

Study locations

1 of 2 sites recruiting
  • Steno Diabetes Center Northern Denmark
    Gistrup, 9260, Denmark
    Recruiting
    • Asbjørn Mohr Drewes, MD, professor · Contactamd@rn.dk · 99321111
    • Christina Brock, professor · Contactchristina.brock@rn.dk · 99326240
    • Asbjørn Mohr Drewes, MD, professor · Principal investigator
  • Steno Diabetes Center Copenhagen
    Herlev, 2730, Denmark
    Not yet recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2028, 32 months after the start.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 32 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Apr 2, 2025
StartActual
May 2, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06906081
Lead sponsor
Peter Rossing
Collaborators
Steno Diabetes Center Nordjylland, Aarhus University Hospital
Responsible party
Peter Rossing (MD, professor, Steno Diabetes Center Copenhagen) — Sponsor-investigator
First posted
Apr 2, 2025
Start date
May 2, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 25, 2025

Study contacts

Peter Rossing, Professor, MD
Contact
peter.rossing@regionh.dk
+4530913383
Christian Stevns Hansen, Ph.D, MD
Contact
christian.stevns.hansen@regionh.dk
+4561671618
Peter Rossing, Professor, MD
principal investigator · Steno Diabetes Center Copenhagen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion